Raphael Pharmaceutical Inc. (OTCPK: RAPH)
Health Care · Biotechnology · IL
$1.51
— today · +51.0% 1Y
Raphael Pharmaceutical Inc. (OTCPK: RAPH) operates in the Biotechnology industry within the Health Care sector. The company is valued at $30.47M and employs 0 people.
Over the last twelve months the share price has gained 51.0%, trading between 0.04 and 1.51.
Tweenvest scores Raphael Pharmaceutical Inc. across four factors: quality 21/100, value 57/100. Its strongest factor is value.
RAPH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $30.47M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.05
- Dividend yield
- —
- Beta (5Y)
- 1.93
- 52-week high
- $1.51
- 52-week low
- $0.04
- Avg volume (3M)
- —
- Shares outstanding
- 20.18M
- Employees
- 0
- Next earnings
- —
About Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life. Currently, the company's leading investigational drug candidate is being advanced for the management of rheumatoid arthritis. Furthermore, Raphael Pharma plans to broaden its pipeline to include more cannabinoid-based medicines aimed at various cancer types and other autoimmune conditions. The company's corporate headquarters are situated in Tel Aviv-Jaffa, Israel.
- ISIN
- US27785B2088
- Listed since
- Jan 5, 2023
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Medicure Inc.TSXV: MPH | $31.36M | CA$4.25 | +42.62% |
| Organoidsciences Ltd.KOSDAQ: A476040 | $31.32M | ₩6,340.00 | -7.45% |
| Oncocross Co., Ltd.KOSDAQ: A382150 | $31.31M | ₩3,200.00 | -12.45% |
| Sernova Biotherapeutics IncTSX: SVA | $30.70M | CA$0.12 | 0.00% |
| Metagenomi Therapeutics, Inc.NasdaqGS: MGX | $30.43M | $0.81 | -1.30% |
| HLB Pep Co., Ltd.KOSDAQ: A196300 | $30.38M | ₩4,320.00 | -17.24% |
| Genenta Science S.p.A.NasdaqCM: GNTA | $30.38M | $0.63 | -0.01% |
| Aligos Therapeutics, Inc.NasdaqCM: ALGS | $30.35M | $4.86 | -8.99% |
Figures last refreshed Oct 18, 2026.